Novartis Pairs a First-in-Class FDA Clearance With 46 Upcoming MS Abstracts
Published on 10/11/2026 at 16:50 | Editorial boerse-global.de
Novartis closed out the first week of October with two distinct pieces of news: a regulatory win for one of its molecules and a fresh licensing deal that widens its reach into RNA-based medicine. The Swiss drugmaker also confirmed it will take the stage at MSToronto2026 with a sizable slate of multiple sclerosis research, and it plans to walk investors through the headline dataset by phone.
Rhapsido Clears FDA Hurdle
The FDA on Wednesday approved Rhapsido, whose active ingredient is remibrutinib, as the first treatment for adults with symptomatic dermographism — a skin condition in which hives are triggered by physical pressure. The label covers patients whose symptoms are not adequately controlled by H1 antihistamines. It marks a completed regulatory step for remibrutinib in one indication, though it does nothing to settle the question of how the same compound will perform in neurology.
That question is what the coming weeks will address. Novartis intends to present late-stage Phase III data from the REMODEL-1 and REMODEL-2 trials of remibrutinib in multiple sclerosis at MSToronto2026, and has scheduled a conference call so investors can discuss the findings. The company is contributing 46 abstracts in total to the congress, spanning its broader MS portfolio rather than focusing on remibrutinib alone. Kesimpta data will feature among them.
Announcement Is Not Evidence
The distinction matters for anyone weighing the stock. A scheduled presentation is not a study readout, and a readout is not an approval. Nothing about the upcoming congress implies either a trial success or a regulatory green light in MS — the content of the data remains the sole thing that will move the needle. The investor call creates a dedicated forum for interpretation, but it cannot substitute for results that have yet to be published.
Should investors sell immediately? Or is it worth buying Novartis?
A $575 Million Bet on mRNA
Running alongside its internal pipeline work, Novartis signed a worldwide exclusive license on October 2 with Abogen Biosciences for ABO2203, an mRNA candidate, alongside options on additional RNA programs. Abogen disclosed a upfront payment of USD 575 million. Should every option be exercised and all agreed milestones be hit, Abogen could collect as much as roughly USD 7.2 billion, plus potential royalty payments.
The structure deserves careful reading. The options are not exercised rights, and the transaction itself remains subject to customary conditions, including regulatory clearances. The headline figure is therefore not a committed lump sum but a ceiling contingent on future steps and successes — a distinction that separates the deal's strategic promise from any immediate financial obligation.
Data Infrastructure, Then the Numbers
A third thread runs through the research stack. CAS and Novartis Biomedical Research announced on September 29 a collaboration to curate and make searchable experimental reaction data, with plans for a bespoke platform supporting AI-driven discovery. This touches how research data is used, not whether any drug wins approval, and it complements both the clinical programs and the licensing arrangement at the technology layer.
Novartis has set October 27 as its next financial appointment, when it will report third-quarter and first-nine-month 2026 results. Until then, the research initiatives and the Abogen agreement supply strategic context — but they stand apart from the clinical readouts and the hard numbers by which investors will judge operating momentum.
Ad
Novartis Stock: New Analysis - 11 October
Fresh Novartis information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
